ACAD Q1 2018 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$49M+219.7% YoY

Gross Profit

$45M92.9% margin

Operating Income

-$55M-112.2% margin

Net Income

-$54M-111.1% margin

EPS (Diluted)

$-0.44

QoQ Revenue Growth

+12.2%

Cash Flow

Operating Cash Flow

-$45M

Free Cash Flow

-$46M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$351M

Total Liabilities

$47M

Stockholders' Equity

$304M

Cash & Equivalents

$116M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$49M	$15M	+219.7%
Gross Profit	$45M	$12M	+267.5%
Operating Income	-$55M	-$89M	+38.3%
Net Income	-$54M	-$88M	+38.2%